Massive Bio’s Co-Founder and CEO, Selin Kurnaz, PhD, to Speak at the Prestigious Global Private Capital Conference
Selin Kurnaz, PhD Co-Founder and CEO of Massive Bio, will be joining the distinguished panel of speakers at the upcoming Global Private Capital Conference. This premier event, held in partnership with the International Finance Corporation (IFC), serves as a nexus for global investors and thought leaders from diverse sectors, including private equity, venture capital, and more. The conference is renowned for its focus on sustainable, long-term investing and the pivotal role of innovation and technology as the harbingers of opportunity.
Massive Bio, under the visionary leadership of Selin Kurnaz, has been at the vanguard of integrating artificial intelligence with oncology to revolutionize cancer treatment. By enhancing access to precision-targeted clinical trials and fostering data-driven treatment decisions, Massive Bio has made significant strides in improving outcomes for cancer patients worldwide. The company’s commitment to democratizing the latest advancements in cancer treatment aligns perfectly with the conference’s emphasis on innovation and sustainable investment.
Selin Kurnaz is set to speak on March 27, 2024, from 2:40 PM to 3:10 PM ET, addressing the theme “The Future of Health: Innovation and Healthtech.” Her session promises to shed light on the transformative impact of AI and technology on healthcare, particularly in oncology, and how these innovations are shaping the future of patient care.
We invite our partners, stakeholders, and anyone interested in the future of health and investment to join us in supporting Selin Kurnaz at this important event. For more information on the conference and how to attend, please visit the Global Private Capital Conference website.
“The Future of Health: Innovation and Healthtech”
March 27, 2024,
2:40 PM – 3:10 PM ET
